Headquartered in Waterloo Exchange, Dublin Fiscal year ends December NASDAQ: JAZZ jazzpharma.com
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases, including epilepsies, cancers, and sleep disorders. Its portfolio includes Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex/Epidyolex (cannabidiol) for epilepsy, Zepzelca (lurbinectedin) for small cell lung cancer, Ziihera (zanidatamab) for HER2-positive biliary tract cancer with a pending indication in first-line gastroesophageal adenocarcinoma, Modeyso (dordaviprone) for recurrent H3 K27M-mutant diffuse glioma, Rylaze for acute lymphoblastic leukemia, Defitelio for hepatic veno-occlusive disease, and Vyxeos for acute myeloid leukemia. The company maintains an active clinical development pipeline centered on zanidatamab across multiple HER2-positive solid tumors and expanded Epidiolex indications, complemented by preclinical research collaborations in T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. Updated
One of Wall Street’s major firms just put its stamp of approval on a specialty pharma name that has been quietly rallying. UBS upgraded Jazz Pharmaceuticals (NASDAQ:JAZZ | JAZZ Price Prediction) to…
David Moadel Pre-Market Stock Futures: Futures are trading lower on Tuesday as the sell-off in technology stocks carried through to Monday and is headed down that road today. All of the major indices, except…
Pre-Market Stock Futures: The futures are trading lower as we get set to conclude one of the zaniest trading weeks the stock market has seen in a long time. Despite crushing analysts’…
Pre-Market Stock Futures: The shortened holiday week is here, and the futures are trading higher this morning. Most traders and investors are returning with a severe case of whiplash after the stock…
With the earnings-reporting season underway, insider buying has been slow. Yet some return buyers continue to build stakes, including huge new purchases in the past week.
The number of notable insider purchases has slowed since the beginning of the year. Yet one huge buy in the past week stood out.
Acquisitions by Warren Buffett and other return buyers highlighted recent insider buying. A biotech company also saw some notable insider interest.
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management. The billionaire is a value investor in the vein of Benjamin…
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re investing…
Tuesday's top analyst upgrades and downgrades included Bill, Carnival, CenterPoint Energy, Editas Medicine, International Paper, Oracle, Palantir Technologies, Petrobras, SentinelOne, Trade Desk, Valvoline and Walmart.
Wednesday's top analyst upgrades and downgrades included AutoZone, EOG Resources, Etsy, Huntsman, Luminar Technologies, Nike, Norwegian Cruise Line, PayPal, Pioneer Natural Resources, Western Digital and Weyerhaeuser.
Wednesday's top analyst upgrades and downgrades included Accenture, Bridgebio Pharma, Chesapeake Energy, eBay, Hewlett Packard Enterprise, Huntsman, New York Community Bancorp, Nucor, Oracle, PBF Energy, Phillips 66, United States Steel and Valero…
Wednesday’s additional top analyst upgrades and downgrades included AbbVie, Bristol-Myers, JetBlue, and more.
Monday's top analyst upgrades and downgrades included Adobe, Anheuser-Busch, Baker Hughes, Chevron, Eli Lilly, Halliburton, Home Depot, Intuit, Microsoft, Robinhood Markets, Shopify, Sirius XM, Southwest Airlines and Walmart.
Tuesday's top analyst upgrades and downgrades included Albertsons, Charles Schwab, Colgate-Palmolive, CyberArk Software, Deckers Outdoor, Dow, Lordstown Motors, Nike, Procter & Gamble and Tesla.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases, including epilepsies, cancers, and sleep disorders.
24/7 Wall St.'s 12-month price target for JAZZ is $308.11, rated Buy. The Wall Street consensus target is $294.27. JAZZ price prediction →
